Clinical Trial Update: Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of tegavivint with gemcitabine in relapsed or refractory osteosarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Tegavivint

Snippet

Sponsor: Emory University | Conditions: Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Status: RECRUITING